Patients who switched from risperidone to lurasidone experienced reductions in several adverse effects, proportionate to increases experienced while on risperidone, according to a study in BMC Psychiatry.
Patients with an acute exacerbation of schizophrenia who received an investigational antipsychotic drug had significantly greater improvement in the PANSS total score, compared with those who received placebo, according to a published study.
Sustained use of the antipsychotic olanzapine in patients with remitted psychotic depression was associated with a thinning of the cortex, when compared with placebo, according to a study published online in JAMA Psychiatry.
Successfully treating reduced motivation, or avolition, in patients with schizophrenia has a positive effect on other negative symptoms, according to a study published online in Schizophrenia Bulletin.
Long-term use of antipsychotics by patients with schizophrenia does not increase the risk of hospitalization for comorbid conditions—and is actually associated with substantially decreased mortality, according to a study in World Psychiatry.